| 摘要 |
A compound of formula (I) is described wherein: W is N or CR2; R is H, halogen, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR, COR15 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R1 is an optionally substituted C1-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl group or an optionally substituted 8-to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N,O or S; R2 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or heteroaryl group each optionally substituted; R3 and R4 are each independently H or an optionally substitutedC1-C6alkyl group; R5 and R6 are each independently H or a C1-C6alkyl,C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R5 and R6 may be taken together with the atom to which they are attached to form an optionally substituted 5-to 8-membered ring optionally containing an additional heteroatom selected from O, NR16 or SOx; m is 0, 1, 2 or 3; n is 2, 3, 4 or 5; p and x are 0, 1 or 2; R7, R8, R11 R15 and R16 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; R9 and R10 are each independently H or a C1-C6alkyl or C3-C7cycloalkyl group each optionally substituted or R9 and R10 may be taken together with the atom to which they are attached to form a 5-to 7-membered ring optionally containing another heteroatom selected from O, NR18 or S; R12 and R13 are each independently H or an optionally substituted C1-C4alkyl group or R12 and R13 may be taken together with the atom to which they are attached to form a 5-to 7-membered ring optionally containing another heteroatom selected from O, NR17, or SOq; R14 is a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; q is 0, 1 or 2; and R17 and R18 are each independently H or a C1-C6alkyl,C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted; or a stereoisomer thereof or a pharmaceutical acceptable salt thereof. The compounds can be used in the manufacture of a medicament for the treatment of a disorder of the central nervous system related to affected by the 5-HT6 receptor, i.e. motor disorder, anxiety disorder, cognitive disorder, neurodegenerative disorder, attention deficit disorder, obsessive compulsive disorder, stroke or head trauma.
|
